IGS1.MU Stock Analysis
IG
Uncovered
India Globalization Capital Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The company is headquartered in Potomac, Maryland and currently employs 52 full-time employees. The company went IPO on 2006-04-13. The firm's segments include Life Sciences and Infrastructure. The Life Sciences segment operates primarily through wholly owned subsidiaries, including IGC Pharma LLC, a clinical-stage biopharmaceutical company based in Maryland. The purpose of IGC Pharma LLC is to treat Alzheimer's patients and alleviate caregiver burden. The Life Sciences segment also includes the development of over-the-counter personal care products, operated by certain of the Company's subsidiaries under various brands. The Infrastructure segment involves the execution of construction contracts and the rental of heavy construction equipment. The company has two main investigational drug assets, which are IGC-AD1 and TGR-63. Its lead therapeutic candidate, IGC-AD1 is in Phase II trials for treating agitation in dementia from Alzheimer's and TGR-63, an enzyme inhibitor to reduce neurotoxicity in Alzheimer's cell lines.